S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover

Zynerba Pharmaceuticals (ZYNE) Stock Forecast & Price Target

Notice: This company has been marked as potentially delisted and may not be actively trading.

Zynerba Pharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 4 Analyst Ratings

Analysts' Consensus Price Target

$1.11
-14.62% Downside
High Forecast$1.11
Average Forecast$1.11
Low Forecast$1.11
TypeCurrent Forecast
2/25/23 to 2/25/24
1 Month Ago
1/26/23 to 1/26/24
3 Months Ago
11/27/22 to 11/27/23
1 Year Ago
2/25/22 to 2/25/23
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$1.11$1.11$1.11$11.00
Predicted Upside-14.62% Downside-17.78% Downside-17.78% Downside780.00% Upside
Get Zynerba Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ZYNE and its competitors with MarketBeat's FREE daily newsletter.


ZYNE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ZYNE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Zynerba Pharmaceuticals Stock vs. The Competition

TypeZynerba PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.25
2.68
2.48
Consensus RatingHoldModerate BuyHold
Predicted Upside-14.62% Downside1,894.50% Upside7.54% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/16/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold$10.00 ➝ $1.11-17.78%
8/15/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
8/14/2023LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
3/31/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Duncan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 04:56 AM ET.












ZYNE Price Target - Frequently Asked Questions

What is Zynerba Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 4 analysts in the last year, the consensus rating for Zynerba Pharmaceuticals stock is Hold based on the current 3 hold ratings and 1 buy rating for ZYNE. The average twelve-month price prediction for Zynerba Pharmaceuticals is $1.11 with a high price target of $1.11 and a low price target of $1.11. Learn more on ZYNE's analyst rating history.

Do Wall Street analysts like Zynerba Pharmaceuticals more than its competitors?

Analysts like Zynerba Pharmaceuticals less than other Medical companies. The consensus rating for Zynerba Pharmaceuticals is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how ZYNE compares to other companies.

Does Zynerba Pharmaceuticals's stock price have much downside?

According to analysts, Zynerba Pharmaceuticals's stock has a predicted downside of -17.78% based on their 12-month stock forecasts.


Stock Ratings Reports and Tools

This page (NASDAQ:ZYNE) was last updated on 2/25/2024 by MarketBeat.com Staff